Catalyst Wire Dossier Catalyst Wire Dossier

ARYS-01 cream 3%

sorivudine · aRigen Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARYS-01 cream 3%, covering 2008-10-07 to 2008-10-07. Get the full timeline:

Most recent: Clinical Trial Update: Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles) [Phase 2]

See pricing